ADME vs EMR

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADME as a result. In 63 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for ADME turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 37 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

ADME moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +0.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADME advanced for three days, in 273 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

ADME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 312 of 356 cases where ADME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EMR as a result. In 55 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.

The Moving Average Convergence Divergence (MACD) for EMR just turned positive on October 27, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in 28 of 44 cases over the following month. The odds of a continued upward trend are 64%.

Following a +2.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 217 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

The Aroon Indicator entered an Uptrend today. In 150 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.

Bearish Trend Analysis

The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 17 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 30 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.543) is normal, around the industry mean (4.069). P/E Ratio (36.157) is within average values for comparable stocks, (37.908). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.013) settles around the average of (0.031) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).